Zacherle E - Search Results

1

Type 2 Diabetes Disease and Management Patterns Across a Large, Diverse Healthcare System: Issues and Opportunities for Guideline-Directed Therapies.

Blood AJ, Chang LS, Colling C, Stern G, Gabovitch D, Zelle D, Zacherle E, Noone J, Robar C, Aronson SJ, Gaziano TA, Matta LS, Plutzky J, Cannon CP, Wexler DJ, Scirica BM. Blood AJ, et al. Among authors: zacherle e. Am Heart J. 2025 Jan 6:S0002-8703(25)00003-1. doi: 10.1016/j.ahj.2025.01.003. Online ahead of print. Am Heart J. 2025. PMID: 39778759

2

Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.

Sharma A, Mariam A, Zacherle E, Milinovich A, Bauman J, Sugano DS, Noone J, Rajpura JR, Zimmerman RS, Burguera B, Kattan MW, Misra-Hebert AD, Pantalone KM, Rotroff DM. Sharma A, et al. Among authors: zacherle e. Diabetes Obes Metab. 2024 Nov;26(11):5347-5357. doi: 10.1111/dom.15896. Epub 2024 Aug 27. Diabetes Obes Metab. 2024. PMID: 39192531

3

Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.

Blood AJ, Chang LS, Hassan S, Chasse J, Stern G, Gabovitch D, Zelle D, Colling C, Aronson SJ, Figueroa C, Collins E, Ruggiero R, Zacherle E, Noone J, Robar C, Plutzky J, Gaziano TA, Cannon CP, Wexler DJ, Scirica BM. Blood AJ, et al. Among authors: zacherle e. Circulation. 2024 Jun 4;149(23):1802-1811. doi: 10.1161/CIRCULATIONAHA.124.069494. Epub 2024 Apr 7. Circulation. 2024. PMID: 38583146 Clinical Trial.

4

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.

Buse JB, Nordahl Christensen H, Harty BJ, Mitchell J, Soule BP, Zacherle E, Cziraky M, Willey VJ. Buse JB, et al. Among authors: zacherle e. BMJ Open Diabetes Res Care. 2023 May;11(3):e003206. doi: 10.1136/bmjdrc-2022-003206. BMJ Open Diabetes Res Care. 2023. PMID: 37137527 Free PMC article.

5

Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Runken MC, Noone JM, Blanchette CM, Zacherle E, Howden R. Runken MC, et al. Among authors: zacherle e. Am Health Drug Benefits. 2019 Oct;12(6):294-304. Am Health Drug Benefits. 2019. PMID: 31908713 Free PMC article.

6

"Get a Grip on Hypertension": EXPLORING THE USE OF ISOMETRIC HANDGRIP TRAINING IN CARDIOPULMONARY REHABILITATION PATIENTS.

Gordon BDH, Whitmire S, Zacherle EW, Doyle S, Gulati S, Leamy LJ, Marino JS, Bennett JM, Reitzel AM, Swaine IL, Howden R. Gordon BDH, et al. Among authors: zacherle ew. J Cardiopulm Rehabil Prev. 2019 Nov;39(6):E31-E34. doi: 10.1097/HCR.0000000000000468. J Cardiopulm Rehabil Prev. 2019. PMID: 31688513 Clinical Trial.

7

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US.

Guptill JT, Runken MC, Eaddy M, Lunacsek OE, Fuldeore RM, Blanchette CM, Zacherle E, Noone JM. Guptill JT, et al. Among authors: zacherle e. Patient Prefer Adherence. 2019 Apr 30;13:649-655. doi: 10.2147/PPA.S185852. eCollection 2019. Patient Prefer Adherence. 2019. PMID: 31118588 Free PMC article.

8

Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.

Blanchette CM, Noone JM, Stone G, Zacherle E, Patel RP, Howden R, Mapel D. Blanchette CM, et al. Among authors: zacherle e. Med Sci (Basel). 2017 Sep 23;5(4):20. doi: 10.3390/medsci5040020. Med Sci (Basel). 2017. PMID: 29099036 Free PMC article.

9

One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States.

Blanchette CM, Zacherle E, Noone JM, Van Doren BA, Roy D, Howden R. Blanchette CM, et al. Among authors: zacherle e. J Health Econ Outcomes Res. 2017 Jul 21;5(1):65-74. doi: 10.36469/9799. eCollection 2017. J Health Econ Outcomes Res. 2017. PMID: 37664693 Free PMC article.

10

Evaluating cost benefits of combination therapies for advanced melanoma.

Jensen IS, Zacherle E, Blanchette CM, Zhang J, Yin W. Jensen IS, et al. Among authors: zacherle e. Drugs Context. 2016 Jul 15;5:212297. doi: 10.7573/dic.212297. eCollection 2016. Drugs Context. 2016. PMID: 27540409 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters